iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Sanofi India: Limited launches, muted volumes hurting growth

26 Mar 2024 , 03:17 PM

Sanofi has continued to underperform domestic pharma market growth, with its retained India business growing at 6% Cagr over CY18-23 vs IPM growth of 10-11% Cagr, owing to limited contribution from new launches and muted volume growth in its top-3 therapies of Diabetes, Cardiac and Respiratory. With 40% of Sanofi’s India portfolio being under NLEM, analysts of IIFL Securities believe CY24 will be another muted year for Sanofi given there will be no price increase benefit for 40% of its India sales owing to flattish WPI inflation last year, and accordingly analysts of IIFL Securities downgrade the stock from ADD to REDUCE. With the stock having rallied >70% over the past 1yr period led by the proposed demerger of the CHL business, they believe the valuation rerating from the CHL demerger is largely in the price now. Analysts of IIFL Securities TP of ₹8,125 is pegged at ~25x Mar-26 EPS and implies 10% potential downside. 

Limited new launches and muted volume growth continue to impact Sanofi’s India business: 

Per secondary data, Sanofi’s India business grew only 5.9% Cagr over CY20-23 (vs IPM’s 11% Cagr) driven by volume/ price/new launches contribution of 1.5/3.6/0.8% resp. While new launches for Sanofi have been muted, Sanofi’s volumes in its top-3 therapies of Diabetes, Cardiac and Respiratory have also declined 3-6% Cagr over the past 3 years, thereby impacting company’s overall performance in India. Scale-up in Toujeo also seems to be impacting Lantus’ growth, with Toujeo/Lantus’ volumes growing 33/1% respectively in CY23. 

Analysts of IIFL Securities believe new launches are already factored in their estimate of 8% Cagr for Sanofi’s India sales over CY23-26: 

Mgmt is targeting 3 new product launches by Mar/Apr-24, which includes Soliqua, Insutage and Cetaphin-S. With Sanofi consolidating its Diabetes portfolio under one unit, mgmt is hopeful that Soliqua’s launch will enable the company to participate in the pre-mix Insulin market in India which is equally large as the basal Insulin market (where Sanofi competes through Lantus and Toujeo).

CHL demerger on track to get completed by Q2CY24: 

Based on Sanofi’s past disclosures, analysts of IIFL Securities estimate that CHL business contributes sales of Rs7.5-7.8bn, accounting for 35% of Sanofi’s domestic sales. Key CHL brands of Allegra, Combiflam, Depura and Avil have grown at 8-9% Cagr over CY20-23 vs Sanofi’s overall India business growing at 6% Cagr. Assuming 30% margins and 35x trailing EV/Ebitda, the CHL business could be valued at an EV of USD1bn, accounting for 40% of Sanofi’s current EV.

Related Tags

  • Sanofi India
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp